Generic Qlosi Availability
Last updated on Nov 6, 2024.
Qlosi is a brand name of pilocarpine ophthalmic, approved by the FDA in the following formulation(s):
QLOSI (pilocarpine hydrochloride - solution;ophthalmic)
-
Manufacturer: ORASIS PHARMS
Approval date: October 17, 2023
Strength(s): 0.4% [RLD]
Has a generic version of Qlosi been approved?
No. There is currently no therapeutically equivalent version of Qlosi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qlosi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent 10,639,297
Issued: May 5, 2020
Inventor(s): Feinbaum Claes & Salamun Franc & Patel Sudhir
Assignee(s): Orasis Pharmaceuticals Ltd.The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
Patent expiration dates:
- August 18, 2037✓✓
- August 18, 2037
-
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent 11,129,812
Issued: September 28, 2021
Inventor(s): Feinbaum Claes & Salamun Franc & Patel Sudhir
Assignee(s): ORASIS PHARMACEUTICALS LTD.The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
Patent expiration dates:
- August 18, 2037✓
- August 18, 2037
-
Patent 11,974,986
Patent expiration dates:
- August 18, 2037✓
- August 18, 2037
-
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent 9,867,810
Issued: January 16, 2018
Inventor(s): Feinbaum Claes & Salamun Franc & Patel Sudhir
Assignee(s): Orasis Pharmaceuticals Ltd.The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
Patent expiration dates:
- August 18, 2037✓✓
- August 18, 2037
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 17, 2026 - NEW PRODUCT
More about Qlosi (pilocarpine ophthalmic)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Breastfeeding
Patient resources
Other brands
Vuity, Isopto Carpine, Pilocar, Ocu-Carpine, Pilopine HS
Professional resources
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate (Ophthalmic) monograph
- Pilocarpine Eye Drops (FDA)
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
